Combination low-dose lymphoblastoid interferon and thymosin alpha 1 therapy in the treatment of chronic hepatitis B.

Rasi G, Mutchnick MG, Di Virgilio D, Sinibaldi-Vallebona P, Pierimarchi P, Colella F, Favalli C, Garaci E

Journal of viral hepatitis1 Jul 1996Cited by 37 (Europe PMC)

PMID8871880DOI10.1111/j.1365-2893.1996.tb00094.xPepBankPUB-08871880

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

01HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In 15 patients with chronic hepatitis B, a regimen of thymosin alpha‑1 with low-dose lymphoblastoid IFN-alpha gave a response in 60% of patients: loss of serum HBV DNA and normal ALT.
In plain wordsIn adults with chronic hepatitis B, thymosin alpha‑1 given together with interferon led to a response in 60% of 15 patients.
Peptide
Thymosin alpha-1
Outcome
Not applicableResponse (loss of serum HBV DNA and normal ALT)
Study
n = 15
Outcome group
Antiviral activity · Liver
Measurements
responders
60%
15 patients
Source sentences
Summary
Nine (60%) of the 15 patients, including six (55%) of the 11 patients previously treated with IFN-alpha 2b, responded by losing serum HBV DNA and normalizing alanine aminotransferase (ALT) values
2 context sentences(design, population, supporting numbers)
Summary · context
This open label study was initiated to assess the safety and efficacy of lymphoblastoid interferon-alpha (IFN-alpha) and thymosin alpha 1 (T alpha 1) in the treatment of 11 patients with chronic hepatitis B, who had failed to respond to standard IFN-alpha 2b therapy, and in four interferon naive patients.
Summary · context
Patients were followed-up for 12 months.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-0887188001
02HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialSafety outcome
In 15 patients with chronic hepatitis B, no significant adverse effects were observed with thymosin alpha‑1 plus IFN-alpha.
In plain wordsIn adults with hepatitis B, no significant side effects were seen with thymosin alpha‑1 plus interferon.
Peptide
Thymosin alpha-1
Outcome
No significant changeAdverse effects
Study
n = 15
Outcome group
Adverse events · Whole body
Source sentences
Summary
no significant adverse effects were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
This open label study was initiated to assess the safety and efficacy of lymphoblastoid interferon-alpha (IFN-alpha) and thymosin alpha 1 (T alpha 1) in the treatment of 11 patients with chronic hepatitis B, who had failed to respond to standard IFN-alpha 2b therapy, and in four interferon naive patients.
Summary · context
Patients were followed-up for 12 months.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-0887188005
03HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In 11 patients with chronic hepatitis B who had failed IFN-alpha 2b, a regimen of thymosin alpha‑1 with low-dose IFN-alpha gave a response in 55%.
In plain wordsIn adults with hepatitis B who did not respond to interferon before, thymosin alpha‑1 plus interferon led to a response in 55% of 11.
Peptide
Thymosin alpha-1
Outcome
Not applicableResponse in patients previously treated with IFN-alpha 2b
Study
n = 11
Outcome group
Antiviral activity · Liver
Measurements
responders
55%
11 previously treated patients
Source sentences
Summary
Nine (60%) of the 15 patients, including six (55%) of the 11 patients previously treated with IFN-alpha 2b, responded by losing serum HBV DNA and normalizing alanine aminotransferase (ALT) values.
2 context sentences(design, population, supporting numbers)
Summary · context
This open label study was initiated to assess the safety and efficacy of lymphoblastoid interferon-alpha (IFN-alpha) and thymosin alpha 1 (T alpha 1) in the treatment of 11 patients with chronic hepatitis B, who had failed to respond to standard IFN-alpha 2b therapy, and in four interferon naive patients.
Summary · context
Patients were followed-up for 12 months.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-0887188002
04HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In chronic hepatitis B, six of the nine responders to thymosin alpha‑1 with IFN-alpha seroconverted to HBsAg negativity.
In plain wordsIn adults with hepatitis B, six of nine responders to thymosin alpha‑1 plus interferon lost the hepatitis B surface antigen.
Peptide
Thymosin alpha-1
Outcome
Not applicableHBsAg seroconversion among responders
Study
n = 9
Outcome group
Antiviral activity · Liver
Source sentences
Summary
Six of the nine responders seroconverted to HBsAg negativity.
2 context sentences(design, population, supporting numbers)
Summary · context
This open label study was initiated to assess the safety and efficacy of lymphoblastoid interferon-alpha (IFN-alpha) and thymosin alpha 1 (T alpha 1) in the treatment of 11 patients with chronic hepatitis B, who had failed to respond to standard IFN-alpha 2b therapy, and in four interferon naive patients.
Summary · context
Patients were followed-up for 12 months.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-0887188003
05HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In responders with chronic hepatitis B, the Knodell histological activity index improved significantly with thymosin alpha‑1 plus IFN-alpha.
In plain wordsIn adults with hepatitis B who responded to thymosin alpha‑1 plus interferon, liver tissue scores improved.
Peptide
Thymosin alpha-1
Outcome
Not applicableKnodell histological activity index in responders
Study
n = 9
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Significant improvements in the Knodell histological activity index were observed in the responders
2 context sentences(design, population, supporting numbers)
Summary · context
This open label study was initiated to assess the safety and efficacy of lymphoblastoid interferon-alpha (IFN-alpha) and thymosin alpha 1 (T alpha 1) in the treatment of 11 patients with chronic hepatitis B, who had failed to respond to standard IFN-alpha 2b therapy, and in four interferon naive patients.
Summary · context
Patients were followed-up for 12 months.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-0887188004

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
10 Oct 2026, 08:55 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.